Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5787677 | 0.92 | LMNA (0.37) | LMNAPOLBKMT2AMAPTALDH1A1 | |
| SCHEMBL5786654 | 0.91 | LMNA (0.39) | LMNAPOLBKMT2AMAPTALDH1A1 | |
| SCHEMBL6072366 | 0.89 | LMNA (0.36) | LMNAPOLBKMT2AMAPTALDH1A1 | |
| SCHEMBL5787539 | 0.88 | LMNA (0.37) | LMNAPOLBKMT2AMAPTALDH1A1 | |
| SCHEMBL6072505 | 0.87 | IRAK4 (0.36) | LMNAPOLBKMT2AMAPTALDH1A1 | |
| SCHEMBL6072152 | 0.86 | POLB (0.34) | LMNAPOLBKMT2AMAPTALDH1A1 | |
| SCHEMBL6072391 | 0.85 | KMT2A (0.41) | LMNAPOLBKMT2AMAPTALDH1A1 | |
| SCHEMBL5784815 | 0.84 | LMNA (0.36) | LMNAPOLBKMT2AMAPTALDH1A1 | |
| Acetic Acid SCHEMBL6072471 | 0.83 | MAPT (0.39) | LMNAKMT2AMAPTALDH1A1HPGD | |
| SCHEMBL5784799 | 0.83 | DHFR (0.40) | LMNAKMT2AALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270577-B1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-6924292-B2 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1270577-A1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | PDE3B, PDE5A, PDE3A | LMNA 4533/4885POLB 1153/4885KMT2A 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.